Mao Geping Cosmetics (1318) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
27 Aug, 2026Executive summary
Revenue for the six months ended 30 June 2026 rose 26.2% year-over-year to RMB3,267.3 million, driven by strong growth in product sales and increased enrollment in makeup artistry training.
Net profit increased 20.3% year-over-year to RMB806.6 million, with gross profit up 27.1% to RMB2,770.4 million and a stable gross margin of 84.8%.
Colour cosmetics remained the largest contributor, with revenue up 38.3% to RMB1,966.7 million; skincare and fragrance also saw double-digit growth.
Online sales channels outpaced offline, growing 33.2% year-over-year, while offline sales rose 19.9%.
The company maintained a strong liquidity position, with cash and cash equivalents of RMB2,780.8 million and no outstanding borrowings as of 30 June 2026.
Financial highlights
Colour cosmetics revenue: RMB1,966.7 million (+38.3% YoY); skincare: RMB1,212.2 million (+11.5% YoY); fragrance: RMB16.7 million (+46.0% YoY).
Gross profit margin for product sales: 85.3% (vs. 84.8% prior year); net profit margin: 24.7%.
Adjusted net profit (non-HKFRS): RMB815.2 million (+21.2% YoY).
Earnings per share: RMB1.64 (basic and diluted), up from RMB1.37.
Interim dividend proposed: RMB0.62 per share, totaling RMB303.9 million.
Outlook and guidance
Plans to expand offline sales network in higher-tier cities and upscale malls, and to increase online presence through proprietary and third-party platforms.
Focus on developing new products in colour cosmetics, skincare, and fragrance, with continued investment in R&D and overseas expansion.
Exploring strategic investments and acquisitions to diversify the brand portfolio and enhance global competitiveness.
Upgrading membership systems and training facilities to drive customer loyalty and professional development.
Latest events from Mao Geping Cosmetics
- Revenue up 30% and net profit up 36.8% with strong growth in color cosmetics and skincare.1318
H2 2025 - Revenue and net profit surged over 30% year-over-year, with strong growth across all core segments.1318
H1 2025 - Record revenue and profit growth in 2024, with robust online sales and successful Hong Kong IPO.1318
H2 2024